GILD vs KYTX
GILD: A leading biopharmaceutical innovator specializing in life-saving HIV therapies and complex CAR T-cell cancer treatments. KYTX: Kyverna Therapeutics is a late-stage clinical company developing potentially curative CAR T-cell therapies for patients with severe neurologic autoimmune diseases.
Side-by-side fundamentals
| Metric | GILD | KYTX | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $153.57 | $5.84 | |
| Market cap | $190.4B | $361M | |
| Net margin FY2025, SEC XBRL | +28.9% | n/a | |
| Operating margin FY2025, SEC XBRL | +34.0% | n/a | |
| ROE FY2025, SEC XBRL | +37.6% | -69.4% | GILD higher |
| ROA FY2025, SEC XBRL | +14.4% | -54.9% | GILD higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 2.22 | 0.15 | KYTX lower |
| Revenue growth (YoY) FY2025, SEC XBRL | +2.4% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +2.6% | n/a | |
| Dividend yield as of 2026-09-03 | +2.2% | n/a | |
| Dividend streak (yrs) SEC XBRL | 11 | 0 | GILD higher |
| Beta as of 2026-09-03 | 0.36 | 1.76 | |
| 1-year return as of 2026-10-21 close | +23.8% | -18.2% | GILD higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.